Compare AU
Compare QUS vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares S&P 500 Equal Weight ETF (QUS) and the BetaShares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
QUS | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 71 | 59 |
Median incremental investment | $1,027.57 | $920.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,190.34 | $1,988.48 |
Average age group | > 35 | 26 - 35 |
Key Summary
QUS | DRUG | |
|---|---|---|
Strategy | QUS.AX was created on 2014-12-17 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. QUS.AX aims to track the performance of the S&P 500 Equal Weight Index (before fees and expenses). The Index provides exposure to 500 leading listed U.S. companies, with each holding in the index weighted equally. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | CONSTELLATION ENERGY CORP (0.30 %) VISTRA CORP (0.27 %) BROADCOM INC (0.27 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Industrials (15.46 %) Financials (14.55 %) Information Technology (13.49 %) | Other (75.15 %) Communication Services (33.53 %) Health Care (24.75 %) |
Top 3 countries | United States (98.60 %) Switzerland (0.39 %) United Kingdom of Great Britain and Northern Ireland (0.39 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.29 % | 0.57 % |
Key Summary
QUS | DRUG | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | S&P 500 Equal Weighted | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.29 % | 0.57 % |
Price | $54.42 | $8.32 |
Size | $774.802 million | $183.750 million |
10Y return | 105.28 % | N/A |
Annual distribution yield (5Y) | 4.92 % | 1.89 % |
Market | ASX | ASX |
First listed date | 19/12/2014 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
QUS | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 71 | 59 |
Median incremental investment | $1,027.57 | $920.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,190.34 | $1,988.48 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
QUS | DRUG | |
|---|---|---|
Pros |
| |
Cons |
|
QUS | DRUG |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |